Intradermal influenza vaccine and new devices: a promising chance for vaccine improvement

被引：37

作者：

Ansaldi, Filippo ^{[1
]}

Durando, Paolo ^{[1
]}

Icardi, Giancarlo ^{[1
]}

机构：

[1] Univ Genoa, Dept Hlth Sci, I-16132 Genoa, Italy

来源：

EXPERT OPINION ON BIOLOGICAL THERAPY | 2011年 / 11卷 / 03期

关键词：

ANTIBODY-RESPONSES; VIRUS-VACCINE; SEASONAL INFLUENZA; DRIFTED INFLUENZA; DENDRITIC CELLS; IMMUNOGENICITY; SAFETY; IMMUNIZATION; EFFICACY; ADULTS;

D O I：

10.1517/14712598.2011.557658

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Areas covered: This review discusses recent advances in intradermally administered influenza vaccines with particular attention to immunogenicity and safety data from clinical trials performed using appropriate injection systems which, combining consistent injection depth and volume, safety, simplicity and ease-of-use, allowed large scale evaluation. Expert opinion: Substantial experience has been accumulated with Intanza 9 and Intanza 15 mu mu g/IDflu 15 mu mu g, administered using BD's Soluvia<SU (TM)(TM)</SU device, and are the first intradermal trivalent inactivated split-virion influenza vaccines to be licensed for use in 18 -- 59 year adults and in elderly people, respectively. Clinical data showed that they are safe and immunogenic and can offer significant advantages in terms of higher acceptability, higher immunogenicity in the elderly and dose-sparing in adults younger than 60 years when compared with intramuscularly administered vaccine.

引用

页码：415 / 427

页数：13

共 82 条

[1]

Tablan Ofelia C, 2004, MMWR Recomm Rep, V53, P1

[2]

[Anonymous], COCHRANE DATABASE SY

[3] Cross-protection by MF59™-adjuvanted influenza vaccine:: Neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses [J].